APA

Harrison C. N., Gregory W., Hudson G. V., Devereux S., Goldstone A. H., Hancock B., Winfield D., MacMillan A. K., Hoskin P., Newland A. C., Milligan D. & Linch D. C. (19991014). High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. : British journal of cancer.

Chicago

Harrison C N, Gregory W, Hudson G V, Devereux S, Goldstone A H, Hancock B, Winfield D, MacMillan A K, Hoskin P, Newland A C, Milligan D and Linch D C. 19991014. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. : British journal of cancer.

Harvard

Harrison C. N., Gregory W., Hudson G. V., Devereux S., Goldstone A. H., Hancock B., Winfield D., MacMillan A. K., Hoskin P., Newland A. C., Milligan D. and Linch D. C. (19991014). High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. : British journal of cancer.

MLA

Harrison C N, Gregory W, Hudson G V, Devereux S, Goldstone A H, Hancock B, Winfield D, MacMillan A K, Hoskin P, Newland A C, Milligan D and Linch D C. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. : British journal of cancer. 19991014.